Triptorelin
Also known as: Trelstar, Triptodur, Decapeptyl, Gonapeptyl, Pamorelin, Diphereline, triptorelin pamoate, triptorelin embonate, triptorelin acetate, [D-Trp6]-GnRH, [D-Trp6]-LHRH
Trelstar (2000): advanced prostate cancer; Triptodur (2017): central precocious puberty, age 2+. Approved in the EU and other countries under several brands with country-specific indications.
4 notable studies · 6 references
TLDR
Triptorelin is a potent synthetic GnRH agonist and an approved drug (Trelstar for advanced prostate cancer, Triptodur for central precocious puberty in the U.S.; Decapeptyl and others elsewhere). A short exposure triggers a surge in reproductive hormones, while sustained exposure shuts down testosterone and estrogen production reversibly. Strong clinical evidence supports its approved uses, and a single dose is also used in IVF to trigger egg maturation with lower risk of ovarian hyperstimulation.
At a Glance
Classification: Synthetic decapeptide gonadotropin-releasing hormone (GnRH/LHRH) agonist analog; hormonal therapy agent
Triptorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), the brain's master signal for the reproductive hormone system. One amino acid is swapped (glycine at position 6 becomes D-tryptophan), which makes it far more resistant to breakdown and much more potent than natural GnRH. It is an approved prescription drug in many countries. In the United States: • Trelstar is approved for palliative treatment of advanced prostate cancer (first approved in 2000). • Triptodur is approved for central precocious puberty (early puberty) in children aged 2 years and older (approved in 2017). In Europe and elsewhere, triptorelin products (such as Decapeptyl, Gonapeptyl, Pamorelin and Diphereline) are also used for indications that include endometriosis, uterine fibroids, assisted reproduction and some breast-cancer settings, depending on country and product. The paradox that defines GnRH agonists: Brief exposure → a surge in LH and FSH, and so in testosterone or estrogen ("flare") Continuous exposure → the pituitary's GnRH receptors desensitize → LH and FSH fall → testosterone or estrogen drops to very low levels. Long-acting depot formulations exploit the second effect to switch off sex-hormone production reversibly. In IVF, a single dose is used for the first effect, to trigger egg maturation.
What Is Triptorelin?
Triptorelin is a decapeptide: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2. Native GnRH has glycine at position 6. Replacing it with D-tryptophan stabilizes the peptide and increases receptor binding. It belongs to the same drug family as leuprolide, goserelin, buserelin and histrelin, and is related to the diagnostic and research peptide gonadorelin (native-sequence GnRH).
What Are Researchers Studying?
Advanced prostate cancer
Androgen deprivation is a cornerstone treatment for advanced prostate cancer. Trials compare how reliably and quickly triptorelin formulations push testosterone to castrate levels and keep it there. One randomized trial found monthly triptorelin reached castration slightly more slowly than leuprolide but maintained it equally well. A 6-month formulation kept 93% of men castrate through months 2–12.
Central precocious puberty
In children whose puberty starts too early, GnRH agonists pause puberty to protect final height and psychosocial wellbeing. A 6-month triptorelin formulation suppressed LH to prepubertal levels in about 93% of children at month 6, and suppression was maintained through month 12.
Assisted reproduction (IVF)
In stimulation cycles that use a GnRH antagonist, a single dose of a GnRH agonist such as triptorelin can trigger the natural LH surge needed for final egg maturation, instead of hCG. Early work showed this approach can sharply reduce the risk of ovarian hyperstimulation syndrome (OHSS) in high responders. It is now widely used in such patients.
Endometriosis, fibroids and breast cancer
Outside the U.S., triptorelin is used to suppress estrogen in endometriosis and uterine fibroids, and for ovarian suppression in some premenopausal breast-cancer settings. Indications vary by country and product.
Gender-affirming care
GnRH agonists, including triptorelin in some countries, are used for puberty suppression in some adolescents with gender dysphoria. This is an area of active debate and differing national policies, and it is beyond the scope of this profile's evidence review.
How Does It Work?
Triptorelin ↓ binds GnRH receptors on pituitary gonadotrope cells ↓ initial release of LH and FSH (flare, lasting days) ↓ with sustained exposure: receptor desensitization and downregulation ↓ LH and FSH suppressed ↓ testes or ovaries make far less testosterone or estradiol ("medical castration," reversible after stopping) ↓ slows hormone-driven prostate cancer, halts early puberty, and shrinks estrogen-dependent tissue such as endometriosis or fibroids. Known class effects of sustained suppression include hot flushes, reduced libido, loss of bone density with long-term use, and metabolic changes. In prostate cancer, the initial flare can temporarily worsen symptoms.
What Does the Research Show?
Human research
HIGH Decades of randomized and non-comparative clinical trials in prostate cancer, central precocious puberty, and reproductive medicine, plus long-term real-world data.
Animal research
HIGH (historical) Extensive preclinical pharmacology established the GnRH-agonist paradox.
In-vitro research
HIGH GnRH receptor pharmacology is well characterized.
Notable Studies
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report
humanJournal: Human Reproduction. Eight women at high risk of OHSS, stimulated with recombinant FSH plus the antagonist ganirelix, received a single triptorelin bolus instead of hCG. Natural LH and FSH surges followed, 83% of retrieved eggs were mature, no patient developed OHSS, and pregnancies resulted, including the first birth with this approach.
Limitations: Eight-patient preliminary report without a control group. The authors called for randomized trials, which later followed.
View publication →Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer
humanJournal: BJU International. 284 men with advanced prostate cancer were randomized to monthly triptorelin or leuprolide for 9 months. At day 29, fewer triptorelin patients were castrate (91.2% vs. 99.3%), but rates were equivalent by day 57 and castration was maintained equally well afterward. Nine-month survival was higher with triptorelin (97.0% vs. 90.5%).
Limitations: The survival difference was a secondary finding over a short period and should not be over-interpreted. Industry-linked study.
View publication →Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study
humanJournal: Clinical Drug Investigation. 120 men with advanced prostate cancer received the 6-month depot formulation. 97.5% reached castrate testosterone by day 29 and 93.0% stayed castrate through months 2–12. The most frequent drug-related side effect was hot flushes (71.7%).
Limitations: Single-arm (no comparator) and 12 months long. Testosterone suppression is a surrogate endpoint rather than survival.
View publication →Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty
humanJournal: Journal of Pediatric Endocrinology and Metabolism. Phase III, non-comparative study in 44 treatment-naïve children (39 girls, 5 boys) with central precocious puberty. 93.2% had prepubertal stimulated LH at month 6, and suppression was maintained, reaching 97.7% at month 12. No unexpected drug-related adverse events were reported.
Limitations: Single-arm and 48 weeks long. Final adult height and long-term outcomes were not assessed.
View publication →What We Still Don't Know
• Long-term bone, metabolic and cardiovascular effects of prolonged androgen deprivation, and how they compare across GnRH agonists and newer GnRH antagonists • Comparative overall survival benefit of triptorelin versus other GnRH agonists; most head-to-head data use testosterone suppression as a surrogate • Long-term outcomes such as adult height, fertility and bone health after the newer long-acting pediatric formulations • Optimal agonist-trigger strategies in IVF for different patient groups • Outcomes of any non-medical use; such use has not been studied in controlled trials.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Triptorelin research with you.
Get the Aminodex Triptorelin Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod. 2000;15(9):1965–1968.
- Heyns CF, Simonin MP, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226–231.
- Lundström EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29(12):757–765.
- Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241–1248.
- Bertelloni S, Mucaria C, Baroncelli GI, Peroni D. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. Expert Rev Clin Pharmacol. 2018.
- Ploussard G, Mongiat-Artus P. Triptorelin in the management of prostate cancer. Future Oncol. 2013.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.